Deerfield
Portfolio in United States: 2 funded startups tracked by Uback, 2 of them in a ranking.
Portfolio on Uback2startups, 1 country
In a ranking2ranked by AI-estimated valuation
On the Radar0eligible, not ranked
Latest deal trackedApr 2026Ray Therapeutics
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| SHINE Technologies | #11 Fusion & advanced nuclear | Energy & climate › Generation › Fusion & advanced nuclear | Series E · USD 240M · Feb 2026 | Unicorn |
| Ray Therapeutics | #11 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series B · USD 125M · Apr 2026 | Hundreds of M$ |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
22026
Co-investors
NantWorks · Fidelity · Sumitomo · Oaktree · 4BIO Capital · Adage Capital · Franklin Templeton
Investors that joined the same rounds, as reported by public sources.
Sources. axios.com, drugdiscoverytrends.com, forgeglobal.com, heatmap.news, as cited on each company’s profile.
Last updated: Oct 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.